The Year in Biotech and What’s Ahead in 2024

Episode Summary

Executive Summary: The podcast reviews biotech’s volatile 2023 and looks ahead to 2024, emphasizing sector consolidation, financing stress, and major scientific milestones. Adam Feuerstein says the year ended stronger than it began, driven by approvals including the first CRISPR therapy and a rally in biotech stocks, but layoffs, weak funding, FTC scrutiny, and uneven FDA standards remain major concerns.

Main Topics: Biotech’s volatile 2023 performance (Priority: 5/5): The XBI biotech index swung sharply all year, with early optimism giving way to steep declines before a late-year rebound that left the sector slightly positive. Layoffs, restructurings, and capital scarcity (Priority: 5/5): A large number of biotech companies cut staff or programs as cash runways shortened, exposing the downside of years of easy fundraising and too many companies. Breakthrough approvals in gene editing and obesity (Priority: 5/5): 2023 brought landmark approvals, especially Casgevy as the first CRISPR-based therapy, while GLP-1 drugs continued to reshape biotech’s commercial outlook. Bluebird Bio’s struggles despite approval (Priority: 4/5): Bluebird’s Lyfgenia approval was overshadowed by pricing, black-box warning concerns, and doubts about whether the company can monetize the therapy before cash runs out. FDA consistency and Sarepta controversy (Priority: 4/5): The discussion highlights frustration over uneven FDA standards across divisions, with Sarepta receiving special attention due to accelerated approval and label expansion questions. M&A boom and FTC intervention (Priority: 4/5): Deal activity surged, but FTC actions against transactions and partnerships raised concern about a more aggressive antitrust posture in pharma and biotech. JP Morgan meeting and 2024 outlook (Priority: 4/5): Lower interest rates, a possible IPO reopening, and continued M&A are expected to shape the next year, with attention on gene therapy, MASH, and capital access.

Key Arguments: Biotech’s 2023 stock performance was erratic but ended better than expected, reflecting a sector that was battered for most of the year but recovered late. Layoffs and restructurings were not just cyclical noise; they reflected too many companies created during a period of easy money and insufficient long-term viability. If the Fed cuts rates in 2024, biotech financing conditions could improve, potentially easing pressure on cash-strapped companies and reopening the IPO market. Casgevy marks a landmark scientific and regulatory moment because it is the first approved CRISPR-based medicine for an inherited disease, but commercial uptake remains uncertain. Bluebird’s approval was scientifically meaningful, yet the company’s weak balance sheet and pricing misstep left it at a disadvantage versus Vertex/CRISPR. GLP-1 drugs are expanding beyond obesity into broader therapeutic and behavioral areas, but access, pricing, and insurance coverage may become the key limiting factors. FDA decision-making is perceived as inconsistent across divisions, creating uncertainty about what evidence is actually required for approval. The FTC’s actions suggest greater scrutiny of biotech deals, including partnerships, which could affect one of the sector’s main financing and exit pathways. Despite a strong year for M&A, stock performance across the broader biotech sector remained weak, showing that deal activity and market confidence are not aligned.

Data Points: XBI biotech index performance: Down ~20% in October, then closed up ~3% for the year - Used to illustrate biotech’s volatile 2023 trading pattern and late-year recovery Layoff/ramp pressure: Hundreds of biotech microcaps - Described as having less than a year of runway based on cash burn Drug approvals in 2023: 55 and counting - Near year-end tally cited as well above prior-year totals Drug approvals in 2022: 37 - Referenced for comparison with 2023’s higher approval count Roy Vant acquisition value: $7.1 billion - Value of the Roivant deal that brought Televant and its IBD drug into the company Pfizer payment for asset later sold by Roivant: About $50 million - Used to show the dramatic return on the Televant transaction Televant sale price after Pfizer origin: About $5 billion - Approximate value achieved after Pfizer had originally paid little for the asset Bluebird stock move on approval news: Fell more than 40% - Reaction to Lyfgenia approval despite the positive regulatory milestone Lyfgenia price: $3.1 million - Bluebird priced its sickle cell gene therapy above Vertex’s Casgevy Casgevy price: $2.2 million - Used as the comparator that undercut Bluebird’s pricing strategy Bluebird financing: $125 million raised - Capital raise discussed as evidence of the company’s weak market leverage Bluebird financing target: $150 million sought - Amount Bluebird reportedly wanted before settling for less Pfizer stock performance: Down ~50% - Cited as part of the rationale for naming Albert Bourla worst CEO M&A activity: Roughly doubled in transaction value - Characterized 2023 as a strong year for biotech/pharma dealmaking JP Morgan event timing: Monday, January 8, 6 PM to 9 PM - Referenced as the venue for Stat’s biotech event featuring Peter Marks

Pivotal Quotes: "“The first medicine based on the CRISPR gene editing technology to win approval in an inherited disease.”" — Adam Feuerstein: Explaining why Casgevy is a landmark approval "“There are just too many biotech companies out there.”" — Adam Feuerstein: Summarizing the structural overexpansion that led to layoffs and restructurings "“Some divisions are harder than others. Some are easy. Some are hard.”" — Adam Feuerstein: Describing inconsistent FDA standards and decision-making across divisions

Implications: 2024 could improve if rates fall and financing opens, but cash-strapped biotechs, unclear FDA expectations, and FTC scrutiny may keep pressure on the sector. Scientific breakthroughs will continue, yet commercial execution and capital access will likely determine winners.